home / stock / vrca / vrca quote
Last: | $6.65 |
---|---|
Change Percent: | 0.0% |
Open: | $6.79 |
Close: | $6.65 |
High: | $6.9499 |
Low: | $6.6 |
Volume: | 297,436 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.65 | $6.79 | $6.65 | $6.9499 | $6.6 | 297,436 | 04-25-2024 |
$6.79 | $6.81 | $6.79 | $6.86 | $6.65 | 114,880 | 04-24-2024 |
$6.85 | $6.78 | $6.85 | $6.95 | $6.72 | 86,259 | 04-23-2024 |
$6.79 | $6.95 | $6.79 | $7 | $6.57 | 311,344 | 04-22-2024 |
$6.98 | $6.87 | $6.98 | $7.01 | $6.78 | 125,739 | 04-19-2024 |
$6.9 | $7.06 | $6.9 | $7.06 | $6.8 | 202,527 | 04-18-2024 |
$7.06 | $7.05 | $7.06 | $7.135 | $6.91 | 105,357 | 04-17-2024 |
$7 | $6.84 | $7 | $7.15 | $6.84 | 89,905 | 04-16-2024 |
$6.92 | $6.87 | $6.92 | $6.955 | $6.7675 | 163,836 | 04-15-2024 |
$6.87 | $7 | $6.87 | $7.17 | $6.75 | 184,162 | 04-12-2024 |
$7.07 | $7.19 | $7.07 | $7.2 | $6.89 | 123,881 | 04-11-2024 |
$7.19 | $6.91 | $7.19 | $7.32 | $6.905 | 192,525 | 04-10-2024 |
$7.05 | $7 | $7.05 | $7.3 | $6.9053 | 95,216 | 04-09-2024 |
$7 | $6.75 | $7 | $7.03 | $6.45 | 196,871 | 04-08-2024 |
$6.73 | $6.36 | $6.73 | $6.76 | $6.355 | 480,562 | 04-05-2024 |
$6.42 | $6.08 | $6.42 | $6.73 | $6.08 | 414,477 | 04-04-2024 |
$6.16 | $5.88 | $6.16 | $6.19 | $5.79 | 106,959 | 04-03-2024 |
$5.89 | $5.6 | $5.89 | $5.95 | $5.6 | 136,717 | 04-02-2024 |
$5.92 | $5.92 | $5.92 | $6.025 | $5.58 | 67,981 | 04-01-2024 |
$5.92 | $5.7 | $5.92 | $6.03 | $5.6 | 92,024 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company...
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President &...
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHEST...